Roche halted the Phase 3 IMAgINATION study due to positive results from Ionis Pharmaceuticals, where sefaxersen showed a clinically meaningful 43.1% reduction in proteinuria, a key kidney repair indicator, relative to placebo at 37 weeks. This achievement is a significant milestone for targeted treatments in IgA nephropathy.